Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:6
  • preuzimanja u poslednjih 30 dana:2
članak: 3 od 8  
Back povratak na rezultate
Praxis medica
2017, vol. 46, br. 3-4, str. 47-52
jezik rada: srpski
vrsta rada: pregledni članak
doi:10.5937/pramed1704047M

Creative Commons License 4.0
Kognitivne funkcije bolesnika sa epilepsijom lečenih topiramatom
aUniverzitet u Prištini, Medicinski fakultet Priština, sedište Kosovska Mitrovica, Kosovska Mitrovica + Kliničko-bolnički centar Priština - Gračanica
bKlinika za neurologiju Kliničkog centra Niš, Niš
cUniverzitet u Prištini (Kosovska Mitrovica), Medicinski fakultet

e-adresa: mmnenad@yahoo.com

Sažetak

Topiramat je noviji lek se jakim antiepileptičkim potencijalom, ali i mogućim neželjenim efektima, posebno na kognitivne funkcije. Ovaj pregled bavi se studijama koje su pratile uticaj topiramata na kogniciju bolesnika sa epilepsijom. Najčešći neželjeni efekti topiramata obuhvatali su somnolenciju, psihomotornu usporenost, otežano pamćenje, poremaćaj koncentracije i pažnje i probleme u govoru. Većina studija je pokazala da visoke početne doze, brza titracija i primena u politerapiji povećavaju rizik od pojave kognitivnih smetnji nakon uveđenja topiramata. Pored toga, depresija i raniji početak bolesti takođe mogu doprineti pojavi kognitivnih neželjenih efekata, čak i pri niskim dozama leka. Iako je topiramat nesporno povezan sa rizikom od pojave kogniitivnih smetnji pojedine studije sugerišu na njihovu reverzibilnost. Ovo, uz visoku antiepileptičku efikasnost, obavezuje istraživače da nastave da tragaju za faktorima rizika i mehanizmima nastanka kognitivnih neželjenih efekata kako bi se definisao profil bolesnika koji bi od leka imali maksimalnu korist u kontroli epileptičkih napada uz odsutne ili prihvatljive neželjene efekte.

Ključne reči

Reference

Aldenkamp, A. P., Baker, G., Mulder, O. G., Chadwick, D., Cooper, P., Doelman, J., Duncan, R., Gassmann-Mayer, C., Haan, G. J., Hughson, C., Hulsman, J., Overweg, J., Pledger, G., Rentmeester, T. W., Riaz, H., Wroe, S. (2000) A Multicenter, Randomized Clinical Study to Evaluate the Effect on Cognitive Function of Topiramate Compared with Valproate as Add-On Therapy to Carbamazepine in Patients with Partial-Onset Seizures. Epilepsia, 41(9): 1167-1178
Aldenkamp, A.P., Arends, J., Bootsma, H.P.R., Diepman, L., Hulsman, J., Lambrechts, D., Leenen, L., Majoie, M., Schellekens, A., deVocht J. (2002) Randomized Double-blind Parallel-group Study Comparing Cognitive Effects of a Low-dose Lamotrigine with Valproate and Placebo in Healthy Volunteers. Epilepsia, 43(1): 19-26
Aldenkamp, A.P., Baker, G. (2001) A Systematic Review of the Effects of Lamotrigine on Cognitive Function and Quality of Life. Epilepsy & Behavior, 2(2): 85-91
Aldenkamp, A.P., Bodde, N. (2005) Behaviour, cognition and epilepsy. Acta Neurologica Scandinavica, 112(s182): 19
Baeta, E., Santana, I., Castro, G., Gonçalves, S., Gonçalves, T., Carmo, I., Caritas, A.I. (2002) Cognitive effects of therapy with topiramate in patients with refractory partial epilepsy. Rev Neurol, 34(8): 737-41
Binnie, C.D. (2003) Cognitive impairment during epileptiform discharges: Is it ever justifiable to treat the EEG?. Lancet Neurol, 2(12): 725-30
Blum, D., Meador, K., Biton, V., Fakhoury, T., Shneker, B., Chung, S., Mills, K., Hammer, A., Isojarvi, J. (2006) Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology, 67(3): 400-406
Bootsma, H.P.R., Ricker, L., Diepman, L., Gehring, J., Hulsman, J., Lambrechts, D., Leenen, L., Majoie, M., Schellekens, A., de Krom, M., Aldenkamp, A.P. (2008) Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison. Seizure, 17(1): 19-26
Bootsma, H.P.R., Coolen, F., Aldenkamp, A.P., Arends, J., Diepman, L., Hulsman, J., Lambrechts, D., Leenen, L., Majoie, M., Schellekens, A., de Krom, M. (2004) Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy & Behavior, 5(3): 380-387
Bootsma, H.R., Aldenkamp, A.P., Diepman, L., Hulsman, J., Lambrechts, D., Leenen, L., Majoie, M., Schellekens, A., de Krom, M. (2006) The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice. Epilepsia, 47(s2): 24-27
Burton, L.A., Harden, C. (1997) Effect of topiramate on attention. Epilepsy Research, 27(1): 29-32
Cramer, J.A., Fisher, R., Ben-Menachem, E., French, J., Mattson, R.H. (1999) New antiepileptic drugs: Comparison of key clinical trials. Epilepsia, 40(5): 590-600
Crawford, P. (1998) An audit of topiramate use in a general neurology clinic. Seizure, 7(3): 207-211
Dooley, J.M., Camfield, P.R., Smith, E., Langevin, P., Ronen, G. (1999) Topiramate in Intractable Childhood Onset Epilepsy - A Cautionary Note. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 26(04): 271-273
Edwards, K.R., Potter, D.L., Wu, S., Kamin, M., Hulihan, J. (2003) Topiramate in the Preventive Treatment of Episodic Migraine: A Combined Analysis From Pilot, Double-Blind, Placebo-Controlled Trials. CNS Spectrums, 8(06): 428-432
Fritz, N., Glogau, S., Hoffmann, J., Rademacher, M., Elger, C.E., Helmstaedter, C. (2005) Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy & Behavior, 6(3): 373-381
Froscher, W., Schier, K.R., Hoffmann, M., Meyer, A., May, T.W., Rambeck, B., i dr. (2005) Topiramate: A prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord, Sep, 7 (3), str. 237-48
Gomer, B., Wagner, K., Frings, L., Saar, J., Carius, A., Härle, M., Steinhoff, B.J., Schulze-Bonhage, A. (2007) The influence of antiepileptic drugs on cognition: A comparison of levetiracetam with topiramate. Epilepsy & Behavior, 10(3): 486-494
Guberman, A., Neto, W., Gassmann-Mayer, C. (2002) Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurologica Scandinavica, 106(4): 183-189
Jones, M.W. (1998) Topiramate - Safety and Tolerability. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 25(S3): S13-S15
Kellet, M.W., Smith, D.F., Stockton, P.A., Chadwick, D.W. (1999) Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry, 66: 759-63
Ketter, T.A., Post, R.M., Theodore, W.H. (1999) Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology, 53: 53-67
Khan, A., Faught, E., Gilliam, F., Kuzniecky, R. (1999) Acute psychotic symptoms induced by topiramate. Seizure, 8(4): 235-237
Kockelmann, E., Elger, C.E., Helmstaedter, C. (2004) Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy & Behavior, 5(5): 716-721
Kwan, P., Brodie, M.J. (2001) Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet, 357(9251): 216-222
Lee, S., Sziklas, V., Andermann, F., Farnham, S., Risse, G., Gustafson, M., Gates, J., Penovich, P., Al-Asmi, A., Dubeau, F., Jones-Gotman, M. (2003) The Effects of Adjunctive Topiramate on Cognitive Function in Patients with Epilepsy. Epilepsia, 44(3): 339-347
Lhatoo, S. D., Wong, I. C. K., Sander, J. W. A. S. (2000) Prognostic Factors Affecting Long-Term Retention of Topiramate in Patients with Chronic Epilepsy. Epilepsia, 41(3): 338-341
Majkowski, J., Neto, W., Wapenaar, R., van Oene, J. (2005) Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine. Epilepsia, 46(5): 648-53
Marson, A. G., Kadir, Z. A., Hutton, J. L., Chadwick, D. W. (1997) The New Antiepileptic Drugs: A Systematic Review of Their Efficacy and Tolerability. Epilepsia, 38(8): 859-880
Martin, R., Kuzniecky, R., Ho, S., Hetherington, H., Pan, J., Sinclair, K., Gilliam, F., Faught, E. (1999) Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology, 52(2): 321-321
Meador, K. J., Loring, D. W., Hulihan, J. F., Kamin, M., Karim, R. (2003) Differential cognitive and behavioral effects of topiramate and valproate. Neurology, 60(9): 1483-1488
Meador, K.J., Loring, D.W., Vahle, V.J., Ray, P.G., Verz, M.A., Fessler, A.J., i dr. (2005) Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology, 64(12): 2108
Meador, K.J. (2008) Cognitive Effects of Levetiracetam versus Topiramate. Epilepsy Currents, 8(3): 64-65
Mecarelli, O., Piacenti, A., Pulitano, P., Vicenzini, E., Rizzo, C., Rinalduzzi, S., de Feo, M.R., Accornero, N. (2001) Clinical and Electroencephalographic Effects of Topiramate in Patients with Epilepsy and Healthy Volunteers. Clinical Neuropharmacology, 24(5): 284-289
Milošević, N. (2009) Analiza faktora rizika za pojavu kognitivnih neželjenih efekata topiramata u terapiji epilepsije. Beograd, Magistarska teza
Milošević, N. (2014) Analiza faktora rizika za pojavu poremećaja egzekutivnih funkcija kod bolesnika sa temporalnom lobarnom epilepsijom. Kosovska Mitrovica, doktorska disertacija
Milošević, N., Sokić, D., Ristić, A., Vitošević, Z., Petrović, N., Trajković, G., Mitrović, V., Vukotić, M., Radić, I. (2009) Depresija kao faktor rizika za razvoj kognitivnih neželjenih efekata topiramata u terapiji epilepsije. Praxis medica, vol. 37, br. 1-2, str. 65-68
Milošević, N., Nenadović, M., Šternić, N., i dr. (2012) Uloga uzrasta na početku epilepsije u pojavi kognitivnih poremećaja nakon uvođenja topiramata. Praxis medica, Vol 41 [3-4]; 1-4
Milošević, N., Sokić, D., Ristić, A., i dr. (2010) Odnos efikasnosti topiramata u kontroli epileptičkih napada i pojave kognitivnih neželjenih efekata. Praxis medica, Vol 38 [1-2]; 61-64
Ortinski, P., Meador, K.J. (2004) Cognitive side effects of antiepileptic drugs. Epilepsy & Behavior, 5: 60-65
Petroff, O.A. C., Hyder, F., Rothman, D.L., Mattson, R.H. (2001) Topiramate Rapidly Raises Brain GABA in Epilepsy Patients. Epilepsia, 42(4): 543-548
Privitera, M., Fincham, R., Penry, J., Reife, R., Kramer, L., Pledger, G., Karim, R. (1996) Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology, 46(6): 1678-1683
Reife, R. A., Pledger, G. W. (1997) Topiramate as Adjunctive Therapy in Refractory Partial Epilepsy: Pooled Analysis of Data from Five Double-Blind, Placebo-Controlled Trials. Epilepsia, 38(s1): S31-S33
Roberts, G.M.P., Majoie, H.J.M., Leenen, L.A.M., Bootsma, H.P., Kessels, A.G.H., Aldenkamp, A.P., Leonard, B.E. (2005) Ketter’s hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam. Epilepsy & Behavior, 6(3): 366-372
Rosenfeld, W.E. (1997) Topiramate: A review of preclinical, pharmacokinetic, and clinical data. Clin Ther, 19(6): 1294-308
Stretton, J., Thompson, P.J. (2012) Frontal lobe function in temporal lobe epilepsy. Epilepsy Research, 98(1): 1-13
Stroop, J. R. (1935) Studies of interference in serial verbal reactions. Journal of Experimental Psychology, 18(6): 643-662
Tatum, W.O., French, J.A., Faught, E., Morris, G.L., Liporace, J., Kanner, A., Goff, S.L., Winters, L., Fix, A., pads Investigators. Post-marketing Antiepileptic Drug Survey (2001) Postmarketing experience with topiramate and cognition. Epilepsia, 42(9): 1134-40
Thompson, P.J. (2000) Effects of topiramate on cognitive function. Journal of Neurology, Neurosurgery & Psychiatry, 69(5): 636-641